X

Trial Profile

Long-term, Open Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of QCC374 in Patients With Pulmonary Arterial Hypertension (PAH)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 Jul 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QCC 374 (Primary)
Indications Pulmonary arterial hypertension
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals

Most Recent Events

17 Feb 2020 Status changed to discontinued.
24 Nov 2018 This trial has been Discontinued in Germany , according to European Clinical Trials Database.
26 Sep 2018 This trial was completed in Germany, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com